Protagonist Therapeutics (PTGX) Other Non-Current Liabilities (2015 - 2021)
Protagonist Therapeutics (PTGX) posted Other Non-Current Liabilities of $121000.0 for Q3 2021, little changed sequentially from $121000.0 in Q2 2021, and down 28.82% YoY from $170000.0 in Q3 2020.
Protagonist Therapeutics (PTGX) Other Non-Current Liabilities (2015 - 2021) Analysis & Trends
Protagonist Therapeutics has reported Other Non-Current Liabilities for 3 years, with the latest figure at $121000.0 in Q3 2021.
- Quarterly Other Non-Current Liabilities fell 28.82% year-over-year to $121000.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $121000.0 (down 28.82% YoY) and the FY2020 annual result came in at $121000.0, changed N/A from the prior year.
- Other Non-Current Liabilities steadied at $121000.0 in Q3 2021 per PTGX's latest filing, from $121000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $170000.0 in Q3 2020 and troughed at $92000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 121,000.00 |
| Jun 30, 2021 | 121,000.00 |
| Mar 31, 2021 | 121,000.00 |
| Dec 31, 2020 | 121,000.00 |
| Sep 30, 2020 | 170,000.00 |
| Jun 30, 2020 | 92,000.00 |
| Dec 31, 2015 | 2.12 Mn |